Suzhou Ribo Life Science, a Chinese drug developer that focuses on liver diseases, has raised a RMB270 million ($40 million) Series B round led by SDIC Fund Management.
Other new investors include China Resources, Zhenghe Yuantong Capital and TusPark Ventures. Existing investors Legend Capital, GGV Capital and Fortune United Partners have also re-upped, according to a...
China healthcare-focused GP C-Bridge Capital and Tasly Holding, a traditional Chinese medicine business, have agreed to invest $150 million in a newly-created entity formed through the merger of two local pharmaceutical companies.
Kuaishou, a Chinese live-streaming video app backed by VC investors and search engine Baidu, has raised $350 million in a new round of funding led by Tencent Holdings.
The Riverside Company has completed its second deal in Malaysia as Drex-Chem Malaysia (now known as DCM Asia), the chemicals distributor it bought in 2014, acquired Erapoly Marketing.
The Carlyle Group has led an investment of more than $100 million in Indian delivery e-commerce logistics service Delhivery. Existing backer Tiger Global Management also took part in the funding round.